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Abstract: 
Controlling muscle function is essential for human behaviour and survival, thus, impairment of 
motor function and muscle paralysis can severely impact quality of life and may be 
immediately life-threatening, as occurs in many cases of traumatic spinal cord injury (SCI) and 
in patients with amyotrophic lateral sclerosis (ALS).  Repairing damaged spinal motor circuits, 
in either SCI or ALS, currently remains an elusive goal. Therefore alternative strategies are 
needed to artificially control muscle function and thereby enable essential motor tasks. This 
review focuses on recent advances towards restoring motor function, with a particular focus 
on stem cell-derived neuronal engraftment strategies, optogenetic control of motor function 
and the potential future translational application of these approaches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Virtually all human behavioural output is governed by motor functions, ranging from locomotion 
and articulated hand movement, to speech and emotional expression. Thus, even minor 
impairment of motor function can have serious implications for the quality of life of affected 
individuals, whilst severe loss of motor function can be immediately life-threatening – as in the 
case of traumatic spinal cord injury (SCI) [1] or neurodegenerative conditions affecting the 
motor system, such as amyotrophic lateral sclerosis (ALS) [2]. To date, efforts to induce 
spontaneous regeneration of trauma-induced lesions within the central nervous system (CNS) 
that affect motor function have not been successful, and there are no existing therapies that 
can delay or reverse the progressive motor neuron degeneration that occurs in ALS, which 
ultimately results in death. Therefore alternative strategies are being sought to repair neural 
circuits that mediate motor control and to artificially restore function to specific muscle groups 
to enable essential motor tasks.  This review will focus on recent advances towards the 
application of these approaches to restore motor function, with a particular focus on the use 
of stem cell-derived neuronal replacement strategies [3], optogenetic control of motor function 
and the potential future translational application of these approaches. 
Stem cell-based therapeutic strategies for spinal motor neurons: the challenges 
In the absence of conventional therapies to restore lost motor function in ALS and SCI, stem 
cell based strategies have provided a promising avenue of research to overcome paralysis 
[4]. Early evidence of lifespan extension in transgenic rodent models of ALS following 
intraspinal transplantation of human neuronal precursor cells (hNPCs) [5] has recently 
progressed to Phase 1 clinical trials in ALS patients, and has proven to be safe and well 
tolerated [6]. However, it is now widely accepted that transplanted hNPCs cannot restore the 
anatomical connectivity of spinal motor circuits or replace lost motor neurons but, rather, they 
provide trophic support that delays the loss of endogenous motor neurons – an effect that is 
restricted to the motor neuron cell body, whilst motor axon integrity and muscle innervation 
are not preserved [7].  
Since the initial method to differentiate murine embryonic stem cells (ESCs) into spinal motor 
neurons was first described [8], a variety of protocols have been developed that enable the 
generation of specific subtypes of motor neurons from stem cells, including human pluripotent 
stem cells [9-11]. Although, this does raise the prospect of more targeted neuronal 
replacement strategies to repair damaged spinal motor circuits using CNS stem cell-derived 
neural grafts [12] to restore motor function, this approach is beset with major difficulties. 
Briefly, these include: i) the absence of developmentally-restricted molecular and genetic 
programs responsible for formation of extremely complex spinal motor circuits [13] [14] , which 
makes it unlikely that grafted motor neurons would functionally integrate into existing, 
damaged motor circuits; ii) the isolation of  intraspinally grafted motor neurons from 
supraspinal inputs; iii) in ALS, the exposure of the grafted neurons to the same toxic 
environment that contributes to the degeneration of the endogenous motor neurons; iv) the 
inhibitory CNS-PNS boundary across which grafted motor neurons would have to extend 
axons out from the spinal cord [15]; v) the great distance along peripheral nerves which any 
grafted neurons would have to grow to innervate specific target muscles, again in the absence 
of developmental axon guidance factors, which would take greater than two years in the 
longest human nerves [16]. In addition, denervated peripheral nerves can only support axonal 
regeneration for a finite period [17], so target innervation by grafted motor axons would have 
to occur within this time. Moreover, this timeframe is longer than the lifespan of many patients 
diagnosed with ALS; finally, vi) during the intervening period between loss of functional 
innervation and growth of the grafted motor axons, target muscles may become irreversibly 
atrophied and cease producing reinnervation cues [18]. It is therefore clear, that strategies 
that depend on transplantation of grafted stem-cell derived motor neurons are not 
straightforward. 
 
Stem cell-based therapeutic strategies targeting peripheral motor nerves 
Strategies targeting the peripheral rather than central nervous system [19] may circumvent 
the challenges described above and this approach has been used to restore specific motor 
functions in animal models [3]. 
Transplantation of motor neurons into peripheral nerves has several important advantages; 
there is no requirement of the grafted motor neurons to integrate into complex spinal motor 
circuits, the neurons are isolated from the toxic/inhibitory environment of the spinal cord, which 
is particularly important in ALS, and the transplanted cells can be placed close to the target 
muscle, near the motor nerve entry point, greatly accelerating the time taken to reinnervate 
the muscle, thereby avoiding diminished schwann cell support of axon growth  and muscle 
atrophy and enabling specific targeting of individual muscles. However, since peripherally 
engrafted motor neurons lack input from the CNS, the activity of these grafted neurons has to 
be elicited by a means of artificial stimulation. 
Artificial control of motor neuron function: Electrical Stimulation 
Functional electrical stimulation (FES) is one approach that has traditionally been employed 
to artificially stimulate motor nerves to induce muscle contraction [20]. FES technology has 
made significant advances over recent years, with the development of implantable electrodes 
capable of differentially controlling multiple muscles to drive coordinated, complex 
movements, such as hand grasping [20]. However, this approach has some fundamental 
drawbacks, particularly in the context of ALS. For example, FES relies on the integrity of the 
motor nerve to induce muscle contraction; although direct electrical stimulation of muscle can 
induce contraction, the voltage required is prohibitively high for sustained use. In ALS, as well 
as cases of contusion-induced loss of motor neurons in SCI, motor axons degenerate resulting 
in loss of and muscle innervation, rendering FES of peripheral nerves redundant. Additionally, 
even when some motor axons remain, electrical stimulation cannot discriminate between 
motor efferent fibres and sensory afferents present in peripheral nerves, so that FES not only 
triggers muscle activity, but also simultaneously activates sensory fibres, including 
nociceptors, which can cause pain, depending on the stimulus intensity. In ALS patients, the 
sensory system remains largely intact and in cases of SCI, although transmission of pain 
signals may be completely blocked, local activation of pain circuits may have unforeseen 
consequences. Most importantly, it is known that FES results in a reversed or random 
recruitment of motor units [21], such that the largest (strongest) most fatigable motor axons 
and the muscles that they innervate are recruited at the lowest stimulus intensity, whilst small 
motor units, which are weaker but more fatigue resistant, are activated by higher intensity 
stimuli. This non-physiological reversal in the graded recruitment of motor unit by FES has 
very significant consequences, most critically, that muscles become rapidly fatigued following 
sustained FES. Thus, for long-term stimulation of muscles, in particular of critical muscles 
such as the diaphragm, the use of FES may be inappropriate, as it is unlikely to support long-
term rhythmic contractions that are essential to maintain breathing. 
Indeed, a recent Phase 1 clinical trial assessing the safety and tolerability of electrical pacing 
of the diaphragm muscle in ALS patients was terminated early due to evidence of decreased 
survival of patients fitted with the device; patient life-expectancy was decreased by an average 
of 11months, compared to patients on non-invasive ventilation alone [22]. Although the 
reasons behind this negative effect of electrical pacing of the diaphragm is not clear from the 
study, it did not appear to be associated with the surgery itself. It is therefore possible that the 
FES resulted in enhanced muscle fatigue, possibly forcing the surviving phrenic motor axons 
to work harder to drive normal respiration, potentially accelerating their degeneration and 
diaphragm muscle denervation. 
Artificial control of motor neuron function: Optical Stimulation 
A solution to the significant drawbacks of FES, in terms of specific and physiological control 
of muscle function, is provided by the now-established technique of optogenetics. 
Optogenetics relies on the biological activity elicited by photosensitive proteins in response to 
light (for a comprehensive review see [23]). Channelrhodpsin-2 (ChR2) is a light-gated ion 
channel originally isolated from algae that, when expressed as a transgene in neurons and 
activated, can depolarize these neurons and trigger action potentials [24]. 
The first demonstration of the use of optogenetics to control motor activity was shown in 
transgenic mice expressing ChR2 under the neuronal Thy1 promoter (Thy1::ChR2 mice). In 
this study, the authors used optical stimulation applied to the primary motor cortex via a 
tethered optical fiber, to induce motor activity [25]. More recently, in Thy1::ChR2 transgenic 
mice, in which ChR2 is expressed in motor neurons, it was shown that motor axons could be 
optically stimulated, using a nerve cuff coupled to a laser light source, to induce highly 
controlled muscle contractions [26]. Importantly, this study also demonstrated that motor units 
activated by optical stimulation are recruited in normal physiological order, with smaller, 
fatigue-resistant motor units being recruited at lower optical stimulus intensities and larger 
fatigable motor units only being activated at higher intensities [26]. The same physiological 
recruitment of ChR2 expressing motor units and prevention of muscle fatigue was also verified 
in our recent study [3], discussed below. Theoretical modelling of the orderly recruitment of 
motor units in peripheral optogenetic neural stimulation (PONS) suggests that the reduced 
internodal distance in small diameter myelinated motor axons is an essential parameter 
underlying this phenomenon [27]. In addition to the major advantage of physiological, graded 
recruitment of motor units, optical stimulation also has the significant advantage that it only 
induces activity in neurons that express the light-responsive opsin. This makes it possible to 
specifically activate motor axons using PONS, and avoids the indiscriminate activation of non-
targeted motor axons as well as nociceptive afferent axons [28]. 
Translational optical control of motor function 
To date, most optogenetic studies investigating motor function in vivo have utilized either 
transgenic mouse models or viral transduction of neurons in rodents and non-human primates 
to express opsins. Although important experimental information has been learned from the 
use of optogenetics in transgenic mice, this is not a viable translational strategy for humans. 
Adeno-associated viruses (AAVs) and other viruses have shown promise as potential gene-
therapy delivery vectors and are capable of targeting opsin expression to specific neuronal 
populations [29], for example to sensory versus motor axons in peripheral nerves in rodents 
[28]. However, whilst viral transduction to express opsins, to enable optogenetic control of 
epileptiform activity for example [30], appears a promising approach, it is not without certain 
disadvantages and risks. For example, it has recently been shown that high-level expression 
of ChR2 in rats, following in utero electroporation, and to a lesser extent viral expression, can 
result in axonal pathology [31], indicating that the level of opsin expression in neurons must 
be carefully controlled. Moreover, in the case of ALS, even if viral transduction could safely 
and effectively deliver appropriate opsins to surviving endogenous motor axons as a 
therapeutic strategy to restore motor function, the ongoing degeneration of these axons and 
resulting muscle denervation would rapidly render the approach ineffective. A third and 
perhaps most translationally viable option would be to take advantage of recent advances in 
gene targeting technology, such as the highly specific CRISPr/Cas9 method [32] [33], along 
with advances in iPSC technology [12], to generate optogenetically-modified neural grafts, 
targeted to peripheral nerves, in order to restore control over paralyzed muscles. Human 
embryonic stem cell-derived neurons that stably express ChR2 have recently been shown to 
survive for >6 months following transplant into SCID mice [34]. This is in agreement with our 
observations of long-term murine ESC-derived motor neuron survival in peripheral nerves of 
wild-type mice (unpublished data).  
Indeed, in a recent study, we developed a combinatorial strategy that utilizes the advantages 
of both stem cell-derived neural engraftment into denervated peripheral motor nerves and 
optogenetic control of motor neuron function, as a translationally relevant approach to 
restoring lost muscle function in mice following nerve injury [3]. In this study, we transplanted 
mouse ESC-derived motor neurons, modified to express ChR2 as well as the neurotrophic  
factor GDNF, into a denervated peripheral nerve of adult mice, and showed that not only were 
these grafted motor neurons able to survive in this peripheral environment, but to also extend 
axons to reinnervate specific target muscles in the hindlimb. Moreover, optical stimulation of 
these ChR2-expressing grafted motor neurons resulted in controlled contraction of the target 
muscles. Importantly, this optically-controlled muscle function avoided the rapid muscle 
fatigue associated with electrical neuromuscular stimulation [3], since optical stimulation of the 
grafted neurons resulted in the normal, physiological recruitment of motor unit, thus confirming 
the findings of other groups [26]. This approach may be ideally suited as a translational 
strategy to enable optical control of the diaphragm muscle in ALS patients, using an optical 
pace-maker to maintain respiratory function. This would avoid the need for mechanical 
ventilation and the problems associated with electrical pacing of the diaphragm muscle [22]. 
Indeed, the ability to experimentally control diaphragm function in rodents, using optogenetics, 
has already been demonstrated [35] and existing pacemaker technology could readily be 
adapted to enable implementation of this approach in the immediate future. 
The combinatorial approach described above demonstrates the advantages of optogenetic 
control of motor function, along with the ability to functionally reinnervate muscles that have 
been paralyzed. However, the next major hurdle to overcome is to develop suitable optical 
stimulation devices to enable chronic control of muscle activity, rather than in our acute proof-
of-principle study [3]. This is essential, since the structure and function of neuromuscular 
junctions (NMJs) are highly dependent on synaptic activity [36], without which, the quiescent 
motor nerve terminal begins to detach from the NMJ and the muscle fiber begins to undergo 
atrophy. Thus optical stimulation devices that can deliver chronic, patterned neuromuscular 
activity are required to maximize the reinnervation and muscle strength achievable using this 
approach. 
Development of implantable optical stimulators  
The significant benefits of optical versus electrical stimulation warrant the rapid development 
of more sophisticated technological and bioengineering solutions to expedite the clinical 
application of this approach. Indeed, major advances have been made towards the 
development of optical stimulation methods in rodent models in the past few years. Initial 
optical stimulation experiments employed tethered optical fibers connected to a laser light 
source [25]. However, whilst this approach has been elegantly used to control muscle function 
in awake freely moving rats, following viral transduction to express ChR2 in peripheral nerves 
[37], it remains technically challenging and impractical for large stimulation experiments 
requiring long-term stimulation; this approach also prohibits normal social behaviour [38,39]. 
A recent elegant study has described the development of fully implantable, wirelessly-powered 
mini-LED devices that are small enough for use in mice, weighing as little as 20mg [40], which 
are likely to greatly facilitate the investigation of optogenetic techniques to control motor 
function in translationally relevant model systems. This is particularly important for 
investigation of motor neuron activation of muscle function, since the formation and 
maintenance of neuromuscular junctions is dependent on chronic, long term stimulation of the 
transplanted neurons and subsequent muscle activity, which is not provided by intermittent 
activation paradigms afforded by tethered systems.  A remaining engineering requirement for 
these devices, in terms of enabling normal control of muscle function, is to enable gradual 
ramping of light intensity to recruit motor units in a normal, graded physiological order and 
thereby avoid muscle fatigue. Nonetheless, this technology represents a significant advance 
towards the ability to reliably control motor function using optogenetics. Indeed, we believe 
that the ability to optically control more complex motor functions, is largely restricted at present 
by the sophistication of optical stimulation devices, since either neural replacement or viral 
transduction strategies can readily confer optogenetic control of spatially discrete, opposable 
muscle groups, at least experimentally [37]. 
Further advances towards optogenetic control of motor function 
An additional requirement for the translational application of optogenetics to control motor 
function is the development and refinement of optimized opsins. As noted above, too high an 
expression level of ChR2 has been shown to induce axonopathy, therefore opsins that enable 
greater (more selective) cation flow and respond to weaker optical stimuli, such as the 
channelrhodopsin Cheriff [41], and the red-shifted channelrhodopsins, ReaChR [42] and 
Chrimson [43]. These red-shifted opsins have the advantage of requiring less energetic 
activation wavelengths in the orange-red spectrum, that have greater tissue penetration, 
thereby enabling more flexibility in terms of optical stimulator development and avoiding 
potential cellular damage from comparatively high-energy blue light [44]. Moreover, further 
characterization of existing optogenetic actuators remains to be undertaken. For example, it 
was recently shown that the well-established neuronal activation by ChR2 is actually reversed 
at lower temperatures and causes inhibition of motor activity in mice under such conditions 
[45]. Indeed, the use of halorhodopsins to block motor activity represents an additional means 
to therapeutically inhibit motor function, which may be of use, for example, in cases of 
spasticity. 
Finally, a recent development in terms of using optogenetics to control muscle function is the 
use of direct optogenetic control of muscle contraction, using both transgenic ChR2 
expressing mice and viral transduction of muscle in vivo, to optically control the muscles of 
the larynx [46]. This approach may provide a complementary therapy to prevent muscle 
wasting in the intervening period between muscle denervation and reinnervation by 
regenerating axons [47]. 
Conclusions 
Recent advances in a range of different fields have resulted in the development of novel 
methods to restore motor function that circumvent the need to repair damage to the CNS, 
which has so far proven to be an elusive goal. By combining the potential of stem cell 
differentiation and the ability to optogenetically control motor neurons, together with the 
development of more sophisticated optical stimulation devices, it may eventually be possible 
to couple this approach with advanced methods that can interpret intended motor output. 
Indeed, a synthesis of brain-machine interface (BMI) technology with FES to control muscle 
function [20] has recently been shown to be a feasible approach to enable overground walking 
in SCI [48], proving that the technolgy to relay motor commands from the brain to target 
muscles already exists. Thus, in the long-term, a combination of intraneural stem cell-derived 
motor neuron engraftment and optogenetics together with BMI may enable paralyzed patients 
to exert control over their own musculature. Recent developments in BMI, from the 
neurotechnology company BrainGate, have produced a device that can wirelessly transmit 
intended motor commands collected from a brain implant to steer a wheelchair or robotic arm 
[49]. Moreover, paralysed patients, some with ALS, are currently taking part in trials of similar 
technology [50]. 
Over the past few years, great progress has been made in the development of the biological 
and technological components that would enable a “body-machine interface” to be constructed 
that would enable optical control of less complex, but essential motor functions, such as 
respiration, swallowing and bowel/bladder function, through the use of optical pacemaker-like 
devices in the near future. The continued development of more sophisticated optical control 
devices, which has already rapidly evolved during the short history of optogenetics, could see 
the longer-term goal of restoring more complex motor functions, such as dexterous hand 
movements and locomotion, come to fruition in the foreseeable future. 
 
 
 
 
 
 
Graphical Abstract Legend: 
Schematic representation of a combinatorial closed-loop system to restore 
functionality to paralyzed muscles, enabling control of specific motor functions. Briefly, 
intraneural grafts of optogenetically-engineered stem cell-derived motor neurons are 
placed closed to the motor-entry point of the target muscle, leading to its reinnervation 
(1) or, where intact, viral vectors are used to express opsins in endogenous motor 
axons. Next, a brain machine interface embedded in the primary motor cortex (2), 
relays intended motor commands via an external neural decoding and processing unit 
(3), which then wirelessly transmits execution signals to an implanted optoelectronic 
stimulator (4) that activates the engrafted motor neurons (5) to induce muscle 
contraction (6). The implanted optoelectronic device can then relay feedback 
information from the muscle or nerve to the processing unit (not shown). 
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